BioCentury
ARTICLE | Company News

Management tracks: VenatoRx builds out development team; plus Arbutus, Cadent and Arsenal Capital

August 21, 2019 11:50 PM UTC

Versant Ventures-backed VenatoRx Pharmaceuticals Inc. (Malvern. Pa.) hired Jennifer Ellis as SVP, quality. She was head of quality assurance at Tracon Pharmaceuticals Inc. (NASDAQ:TCON). The infectious disease company also hired Paul McGovern as VP, medical sciences and Lauren Tornetta as VP, regulatory affairs. McGovern was VP, clinical and medical affairs at Paratek Pharmaceuticals Inc. (NASDAQ:PRTK); and Tornetta was VP, head of regulatory affairs at Galera Therapeutics Inc. (Malvern, Pa.) (see "Safety First").

HPV company Arbutus Biopharma Corp. (NASDAQ: ABUS) named Andrew Cheng to the company's board of directors. He is president and CEO at Akero Therapeutics Inc. (NASDAQ:AKRO) and was CMO and EVP at Gilead Sciences Inc. (NASDAQ:GILD), where he led clinical development for several HIV/AIDS programs...